Free Trial

Hemogenyx Pharmaceuticals (HEMO) Earnings Date, Estimates & Call Transcripts

Hemogenyx Pharmaceuticals logo
GBX 1,191.40 +111.40 (+10.31%)
As of 12:02 PM Eastern

Hemogenyx Pharmaceuticals Earnings Summary

Hemogenyx Pharmaceuticals announced Interim earnings on September 30, 2025, reporting an EPS of -GBX 0.83. Hemogenyx Pharmaceuticals currently has a trailing EPS of -GBX 2.31

Interim Earnings Resources

Latest Interim
Earnings Date
Sep. 30Estimated
Get Hemogenyx Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

HEMO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Hemogenyx Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
9/30/2025Interim-GBX -0.83----
4/28/2025Final-GBX -181.10----


This page (LON:HEMO) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners